Investors in Zynex (NASDAQ:ZYXI) Have Unfortunately Lost 22% Over the Last Five Years
Northland Securities Initiates Zynex(ZYXI.US) With Buy Rating, Announces Target Price $12.5
Northland Securities analyst Owen Rickert initiates coverage on $Zynex(ZYXI.US)$ with a buy rating, and sets the target price at $12.5.According to TipRanks data, the analyst has a success rate of 0.0
Zynex's Strategic Shifts Set Stage for Long-term Success, Analysts Say | NASDAQ:ZYXI
Zynex CEO Reflects on 28 Years of Medical Device Innovation - ICYMI | NASDAQ:ZYXI
In Spite of Recent Selling, Insiders Still Have the Largest Holding in Zynex, Inc. (NASDAQ:ZYXI) With a 51% Ownership
HC Wainwright & Co. Reiterates Buy on Zynex, Maintains $16 Price Target
Zynex Analyst Ratings
H.C. Wainwright Maintains Zynex(ZYXI.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright analyst Yi Chen maintains $Zynex(ZYXI.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 27.9% and a total
Buy Rating Affirmed for Zynex on FDA Clearance and Solid Growth Prospects
Zynex to Present at the HC Wainwright Global Investment Conference
Zynex Gains FDA Clearance for New TensWave Device, Expands Pain Management Solutions | NASDAQ:ZYXI
Zynex Obtains FDA Clearance for New Pain Management Device
Zynex's Bold Expansion in Patient Monitoring Technologies Moves From Vision to Reality | NASDAQ:ZYXI
Zynex's (NASDAQ:ZYXI) Returns On Capital Not Reflecting Well On The Business
Zynex, Inc.'s (NASDAQ:ZYXI) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors
Insider Sale: COO Anna Lucsok Sells 24,875 Shares of Zynex Inc (ZYXI)
Don't Ignore The Insider Selling In Zynex
Zynex Second Quarter 2024 Earnings: Misses Expectations
Why Zynex Plunged Today
Zynex Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 Financial Results and Lowered Its Q3 Guidance Below Estimates. Additionally, Multiple Firms Lowered Their Respective Price Targets on the Stock.